Pivotal readout

GSK's bepirovirsen cure holds for most patients a year after stopping treatment

Final data from the phase 3 B-Well 1 and 2 studies showed 211 of 232 patients who reached functional cure still had it at week 96, nearly a year after all hepatitis B therapy ended. At week 72, 19% of treated patients were cured versus none on placebo. Two Chinese marketing applications remain under priority review.

Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call